Characteristics of Central Retinal Vein Occlusion in African Americans.
African American
antivascular endothelial growth factor (anti-VEGF)
central retinal vein occlusion
panretinal photocoagulation
Journal
Journal of vitreoretinal diseases
ISSN: 2474-1272
Titre abrégé: J Vitreoretin Dis
Pays: United States
ID NLM: 101700301
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
medline:
6
11
2019
entrez:
3
4
2023
pubmed:
6
11
2019
Statut:
epublish
Résumé
This article studies whether the characteristics and clinical course of African American patients with central retinal vein occlusion (CRVO) differ from other racial groups. This retrospective cohort study included consecutive patients diagnosed with CRVO at Duke Eye Center, Durham, North Carolina. Presenting characteristics, examination findings, treatment course, and functional and structural outcomes were compared based on patient-reported race. A total of 479 patients with CRVO were included (64.7% white, 22.2% African American, 1.7% mixed race, and 11.4% other races). African American patients were older (68.1 vs 64.3 years, African Americans with CRVO presented with more severe visual impairment and more systemic and ocular risk factors for CRVO. Treatment-naive African Americans had a greater treatment burden during the first year of follow-up.
Identifiants
pubmed: 37007449
doi: 10.1177/2474126419882829
pii: 10.1177_2474126419882829
pmc: PMC9982256
doi:
Types de publication
Journal Article
Langues
eng
Pagination
186-191Informations de copyright
© The Author(s) 2019.
Déclaration de conflit d'intérêts
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: S.F. receives patent royalties from Alcon and is a consultant to Regeneron. The other authors have nothing to declare.
Références
Br J Ophthalmol. 2008 Oct;92(10):1316-9
pubmed: 18684751
Ophthalmology. 2013 Apr;120(4):803-8
pubmed: 23352194
Ophthalmology. 2010 Jun;117(6):1134-1146.e3
pubmed: 20417567
Graefes Arch Clin Exp Ophthalmol. 1990;228(3):201-17
pubmed: 2361592
Arch Ophthalmol. 1996 May;114(5):545-54
pubmed: 8619763
Arch Ophthalmol. 2009 Sep;127(9):1101-14
pubmed: 19752419
Ophthalmology. 2010 Feb;117(2):313-9.e1
pubmed: 20022117
Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):3331-9
pubmed: 27367500
Ophthalmology. 2012 Apr;119(4):802-9
pubmed: 22301066
Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4297-302
pubmed: 18539932
Ophthalmology. 2010 Jun;117(6):1124-1133.e1
pubmed: 20381871
Arch Ophthalmol. 2006 May;124(5):726-32
pubmed: 16682596
Circulation. 2008 Jan 29;117(4):e25-146
pubmed: 18086926
Retina. 2019 Jun;39(6):1033-1038
pubmed: 29474305
Ophthalmology. 2011 Dec;118(12):2453-60
pubmed: 21764136
Retina. 1981;1(1):27-55
pubmed: 15633406
Trans Am Ophthalmol Soc. 2000;98:133-41; discussion 141-3
pubmed: 11190017
Retina. 2013 Jan;33(1):152-9
pubmed: 22825408
Ophthalmology. 2007 Sep;114(9):1795-6
pubmed: 17822995
JAMA. 2003 May 21;289(19):2560-72
pubmed: 12748199
Arch Ophthalmol. 2010 May;128(5):541-50
pubmed: 20457974
Ophthalmology. 2013 Feb;120(2):362-70
pubmed: 23177364
Arch Ophthalmol. 1996 Oct;114(10):1243-7
pubmed: 8859084
Ophthalmology. 2010 Jun;117(6):1102-1112.e1
pubmed: 20398941
Am J Ophthalmol. 2014 Nov;158(5):1032-8
pubmed: 25068637
Can J Ophthalmol. 1993 Dec;28(7):320-4
pubmed: 8313218